Ascend Wellness Holdings (AAWH) Depreciation & Amortization (CF) (2020 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Depreciation & Amortization (CF) came in at $18.3 million in Q1 2026, down 0.65% year-on-year from $18.4 million in Q1 2025, and down 10.96% quarter-over-quarter from $20.5 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $18.3 million for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 0.65% year-over-year to $18.3 million in Q1 2026; TTM through Mar 2026 was $73.4 million, a 7.68% increase from a year earlier, with the FY2025 full-year figure at $73.5 million, up 11.14% from the prior year.
- Depreciation & Amortization (CF) declined to $18.3 million in Q1 2026 per AAWH's latest filing, from $20.5 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $21.9 million in Q1 2023 and bottomed at $7.3 million in Q2 2023.
- The 5-year median for Depreciation & Amortization (CF) is $16.4 million (2024), against an average of $14.9 million.
- Across the five-year window, Depreciation & Amortization (CF) surged 121.22% in 2023 and decreased 25.35% in 2024, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $11.3 million in 2022, then soared by 31.1% to $14.8 million in 2023, then rose by 18.1% to $17.5 million in 2024, then grew by 17.52% to $20.5 million in 2025, then decreased by 10.96% to $18.3 million in 2026.
- Per Business Quant, the three latest AAWH Depreciation & Amortization (CF) figures stand at $18.3 million (Q1 2026), $20.5 million (Q4 2025), and $16.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Ascend Wellness Holdings | 83.00 Mn | 22.91 Mn | 44.88 Mn | 18.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.28 Mn |
| Mar 31, 2026 | 18.28 Mn |
| Dec 31, 2025 | 20.53 Mn |
| Dec 31, 2025 | 20.53 Mn |
| Sep 30, 2025 | 16.77 Mn |
| Sep 30, 2025 | 16.77 Mn |
| Jun 30, 2025 | 17.83 Mn |
| Jun 30, 2025 | 17.83 Mn |
| Mar 31, 2025 | 18.40 Mn |
| Mar 31, 2025 | 18.40 Mn |
| Dec 31, 2024 | 17.47 Mn |
| Dec 31, 2024 | 17.47 Mn |
| Sep 30, 2024 | 16.63 Mn |
| Sep 30, 2024 | 16.63 Mn |
| Jun 30, 2024 | 15.68 Mn |
| Jun 30, 2024 | 15.68 Mn |
| Mar 31, 2024 | 16.38 Mn |
| Mar 31, 2024 | 16.38 Mn |
| Dec 31, 2023 | 14.79 Mn |
| Dec 31, 2023 | 14.79 Mn |